Journal Articles
Wirshing WC. What is Schizophrenia? Journal of the California Alliance for the Mentally Ill. 1997;8(3):5-8.
McGurk SR, Green MF, Wirshing WC, Ames D, Marshall BD, Marder SR. Risperidone vs. haloperidol on cognitive functioning in treatment-resistant schizophrenia: the trail making test. CNS Spectrums 1997;2(8):60-64.
Kramer M, Last B, D4 Antagonist Study Group. The effects of a selective D4 receptor antagonist (L-745,870) in acutely psychotic schizophrenic patients. Arch Gen Psychiatry 1997; 54(6):567-572.
Aravagiri M, Ames D, Wirshing WC, Marder SR. Plasma Level Monitoring of Olanzapine in Patients with Schizophrenia: Determination by High-Performance Liquid Chromatography with Electrochemical Detection. Therapeutic Drug Monitoring 1997; 19:307-313.
Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk SR, Kern RS, Mintz J. Does Risperidone Improve Verbal Working Memory in Treatment-Resistant schizophrenia? Am J Psychiatry 1997; 154: 799-804.
Wirshing WC, Ames D, Bisheff S, Pierre JM, Mendoza A, Sun A. Hepatic Encephalopathy Associated With Combined Clozapine and Divalproex Sodium Treatment. Journal of Clinical Psychopharmacology 1997; 17: 120-121.
Ames D, Wirshing WC, Baker RW, Umbricht DSG, Sun AB, Carter J, Schooler NR, Kane JS, Marder SR. Predictive Value of Eosinophilia for Neurtropenia During Clozapine Treatment. J Clin Psychiatry, 1996; 57(12): 579-581.
Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, Lebell M, Zimmerman K, Liberman RP. Two-Year Outcome of Social Skills Training and Group Psychotherapy for Outpatients with Schizophrenia. American Journal of Psychiatry 1996;153:1585-1592.
Ames D, Wirshing WC, Marder SR. Advances in Antipsychotic Pharmacotherapy: Clozapine, Risperidone, and Beyond. Essential Psychopharmacology 1996;1:5-26.
He H, McKay G, Wirshing WC, Midha KL. Development and Application of a Specific and Sensitive Radioimmunoassay for Trihexyphenidyl to a Pharmacokinetic Study in Humans. Journal of Pharmeceutical Sciences 1995;84:561-567.
Wirshing WC. Mood Instability. Journal of the California Alliance for the Mentally Ill. 1995;6:5-6.
Ames D, Cokely HT, Lo LL, Wirshing WC. The natural course of psuedotumor cerebri in lithium-treated patients. J Clin Psychopharm 1994;14:286-287.
Altshuler LL, Pierre JM, Wirshing WC, Ames D. Sertraline and akathisia. J Clin Psychopharm 1994;14:278-79.
Ames D, Cummings JL, Wirshing WC, Quinn B, Mahler M. Repetitive and compulsive behavior in frontal lobe degenerations. J Neuropsychiatry and Clin Neuroscience 1994;6:100-113.
Marder SR, Wirshing WC, Van Putten T, Mintz J, Johnston-Cronk K, Lebell M, Liberman RP. Fluphenazine versus placebo supplementation for prodromal signs of relapse in schizophrenia. Arch Gen Psychiatry. 1994;51:280-287.
Wirshing WC. In a perfect world none of this would concern us. Journal of the California Alliance for the Mentally Ill 1994;5:30. (not peer reviewed)
Freedman J, Wirshing WC, Russell AT, Palmer ML, Unitzer J. Absence status seizures during successful long-term clozapine treatment of an adolescent with schizophrenia. Am Acad Child Adolesc Psychiatry 1994;4:53-62.
Frye MA, Wirshing WC, Ames D. Clozapine as a diagnostic tool in a psychotic parkinsonian patient. J Clin Psychopharmacol. 1993;13:360-361.
Midha KK, Marder SR, Jaworski TJ, McKay G, Hubbard JW, Hawes EM, Van Putten T,
Wirshing WC, Aravagiri M. Clinical perspectives of some neuroleptics through development and application of their assays. Therapeutic Drug Monitoring. 1993;15:179 189.
Wirshing WC, Marder SR. Can prodromal states guide low-dose neuroleptic treatment ? Relapse: Issues in the Management of Chronic Psychosis. 1993;3:1-4.
Lebell MB, Marder SR, Mintz J, Mintz LI, Tompson M, Wirshing W, Johnston-Cronk K, McKenzie J. Patients' perceptions of family emotional climate and relapse risk in schizophrenia. Br J Psychiatry. 1993;162:751-754.
Wirshing WC, Van Putten T, Marder SR. Clinical consequences of akinesia and akathisia. Research and Clinical Forums: New Opportunities in the Management of Psychoses 1993;15(2):31-43.
Wirshing WC, Marder SR. Drug treatment in schizophrenia. Current Opinion in Psychiatry 1993;6(1):85-89.
Ames D, Wirshing WC. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome--A possible link (Letter to the Editor). JAMA 1993;269(7):869.
Eckman TA, Wirshing WC, Marder SR, Liberman RP, Johnston-Cronk K, Zimmerman K. Technique for training schizophrenic patients in illness self-management: A controlled trial. Am J Psychiatry 1992;149(11):1549-55.
Wirshing WC, Marder SR, Eckman T, Liberman RP, Mintz J. Acquisition and retention of skills training methods in chronic schizophrenic outpatients. Psychopharmacol Bull 1992;28(3):241-5.
Wirshing WC, Van Putten T, Rosenberg J, Marder S, Ames D, Hicks-Gray T. Fluoxetine, akathisia, and suicidality: Is there a causal connection? (Letter to the Editor). Arch Gen Psychiatry 1992;49:580-1.
Ames D, Wirshing WC, Szuba MP. Organic mental disorders associated with bupropion in three patients. J Clin Psychiatry 1992;53(2):53-5. (Exerpted in Psychiatry Drug Alerts May 1992, pp 35-36, under the title of: Bupropion-related organic mental disorders.)
Kern RS, Green MF, Satz P, Wirshing WC. Patterns of manual dominance in patients with neuroleptic-induced movement disorders. Biol Psychiatry 1991;30:483-92.
Wirshing WC. Schizophrenia, neuroleptics, and brain rust: Speculations from the research fringe. Journal of the California Alliance for the Mentally Ill 1991;2(4):31-4. (not peer reviewed)
Wirshing WC. Searching the brain: Trying to see neurobiological disorders. Journal of the California Alliance for the Mentally Ill 1991;2(4):2-3. (not peer reviewed)
Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N. Neuroleptic plasma levels. Schizophr Bull 1991;17(2):197-216.
Van Putten T, Aravagiri M, Marder SR, Wirshing WC, Mintz J, Chabert N. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. Psychopharmacol Bull 1991;27(2):91-6.
Marder SR, Mintz J, Van Putten T, Lebell M, Wirshing WC, Johnston-Cronk K. Early prediction of relapse in schizophrenia: An application of receiver operating characteristic (ROC) methods. Psychopharmacol Bull 1991;27(1):79-82.
Marder SR, Wirshing WC, Van Putten T. Drug treatment of schizophrenia: Overview of recent research. Schizophrenia Research 1991;4:81-90.
Wirshing WC, Cummings JL, Dencker SJ, May PRA. Electromechanical characteristics of tardive dyskinesia. Journal of Neuropsychiatry and Clinical Neurosciences 1991;3:10-7.
Van Putten T, Wirshing WC, Marder SR. Tardive Meige syndrome responsive to clozapine (Letter to the Editor). J Clin Psychopharmacol 1990;10(5):381-2.
Wirshing WC, Phelan CK, Van Putten T, Marder SR, Engel J. Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesia (Letter to the Editor). J Clin Psychopharmacol 1990;10(5):371-3.
Marder SR, Van Putten T, Aravagiri M, Wirshing WC, Johnson-Cronk K, Lebell M. Clinical and biological predictors of relapse in schizophrenia. Paper given at the 17th Collegium Internationale Neuropsychopharmacologicum (13-10-4). Clin Neuropharmacol 1990;13(suppl 2):432-3.
Van Putten T, Marder SR, Wirshing WC, et al. The clinical significance of a plasma haloperidol and fluphenazine level. Paper given at the 17th Collegium Internationale Neuropsychopharmacologicum. Clin Neuropharmacol 1990;13(Suppl 2):430-1.
Van Putten T, Marder SR, Wirshing WC, Chabert N, Aravagiri M. (Letter to the Editor). Surreptitious noncompliance with oral fluphenazine in a voluntary inpatient population. Arch Gen Psychiatry 1990;4:786-7.
Wirshing WC, Cummings JL. Tardive movement disorders. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1990;3(1):23-35.
Flynn GF, Cummings JL, Scheibel J, Wirshing WC. Monosymptomatic delusions of parasitosis associated with ischemic cerebrovascular disease. J Geriatr Psychiatry Neurol 1989;2(3):134-9.
Wirshing WC, Freidenberg DL, Cummings JL, Bartzokis G. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism. J Clin Psychopharmacol 1989;9(6):407-11.
Cummings JL, Wirshing WC. Recognition and differential diagnosis of tardive dyskinesia. Int J Psychiatry Med 1989;19(2):133-44.
Wirshing WC, Cummings JL. Extrapyramidal syndromes in the elderly: Diagnosis and management. Geriatrics 1989;44(2):47-54.
Bartzokis G, Hill MA, Altshuler L, Cummings JL, Wirshing WC, May PRA (deceased). Tardive dyskinesia in schizophrenic patients: Correlation with negative symptoms. Psychiatry Res 1989;28:145-51.
Bartzokis G, Wirshing WC, Hill MA, Cummings JL, Altshuler L, May PRA. Comparison of electromechanical measures and observer ratings of tardive dyskinesia. Psychiatry Res 1989;27:193-8.
Lelord F, Liberman RP, Eckman T, Wirshing B. A group for training schizophrenic patients in symptom self-control: An ongoing experiment (in French). Annales de Psychiatrie 1988;3(2):156-9.
Cummings JL, Wirshing WC. Quantitative neuropsychiatry: The Brentwood Movement Disorders Laboratory. VA Practitioner 1988;5(2):99-104.
Book Chapters
Wirshing DA, Marder SR, Wirshing WC, Saunders CS, Rossotto EH, Erhart SM:
Atypical antipsychotics: A practical review, Medscape 1997; http://www.medscape.com
Marder SR, Wirshing WC, Ames D. New Antipsychotic Drugs. (pp. 195-207) In: Dunner & Rosenbaum, eds. The Psychiatric Clinics of North America Annual of Drug Therapy. Philadelphia, PA: W.B. Saunders Company, 1997.
Marder SR, Wirshing WC, Ames D: Overview of Antipsychotic Medications. (pp. 211 15) In: Dunner, ed. Current Psychiatric Therapy II (2nd Edition). Philadelphia: W.B. Saunders Company, 1997.
Ames D, Wirshing WC, Marder SR. Advances in Antipsychotic Pharmacotherapy: Clozapine, Risperidone, and Beyond. Ballière's Clinical Psychiatry: Directions in Rehabilitation Counseling, Volume 7, Lesson 9. New York, NY: The Hatherleigh Co., 1996.
Ames D, Marder SR, Wirshing WC, Van Putten T: Ongoing Research in the Treatment of Schizophrenia. (pp. 13-30) In: Kane, Möller, Awouters, eds. Serotonin in Antipsychotic Treatment (1st edition). New York, NY: Marcel Dekker, Inc., 1996.
Ames D, Marder SR, Wirshing WC. Risperidone: Clinical Applications. (pp. 15-40) In: Breier, ed. The New Pharmacotherapy of Schizophrenia (1st Edition). Washington, DC: American Psychiatric Association Press, 1996.
Ames D, Marder SR, Wirshing WC. The Long-Term Treatment of Schizophrenic Disorders. (pp. 511-532) In: Ancill & Lader, eds. Pharmacological Management of Chronic Psychiatric Disorders (1st Edition). Philadelphia, PA: Baillière Tindall, 1995.
Wirshing WC. Neuropsychiatric Aspects of Movement Disorders. (pp.220-231) In: Kaplan HI and Sadock BJ, eds. Compreshensive Textbook of Psychiatry/VI (6th Edition). Baltimore, MD: Williams & Wilkins, 1995.
Wirshing WC, Marder SR, Van Putten T, Ames D. Acute treatment of schizophrenia. (pp.1259-66) In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, 1995.
Wirshing WC, Ames D, Marder SR, Hicks-Gray T. Schizophrenia. (pp 203-220) In: Hersen M, Ammerman R, Sisson L, eds. Handbook of aggressive and destructive behavior in psychiatric settings. New York, NY: Plenum, 1994.
Marder SR, Van Putten T, Aravagiri M, Wirshing WC, Midha KK. Plasma level monitoring for long-acting injectable neuroleptics (pp101-112). In: SR Marder, ed. Clinical Use of Neuroleptic Plasma Levels. Washington DC/London: American Psychiatric Press, 1993.
Marder SR, Ames D, Wirshing WC, Van Putten T. Schizophrenia (pp 567-88). In: DL Dunner (ed.) Psychiatric Clinics of North America. Philadelphia, PA: W.B. Saunders Co., 1993.
Wirshing WC, Marder SR, Van Putten T. Future directions in antipsychotic drug treatment (chap. 88, pp 544-51). In: DL Dunner (ed.), Current Psychiatric Therapy. Philadelphia, PA: W.B. Saunders Co., 1993.
Cummings JL, Wirshing WC. Movement disorders in schizophrenia (chap. 55, pp. 407 13). In: AB Joseph, RR Young, eds. Movement disorders in neurology and neuropsychiatry. Boston/Oxford/London/Edinburgh/Melbourne/Paris/Berlin/Vienna: Blackwell Scientific Publications, 1992.
Marder SR, Van Putten T, Wirshing WC, Aravagiri M, Hicks-Gray T. Subjective experiences of extrapyramidal side-effects in schizophrenia (pp. 590-2). In: G Racagni, N Brunello, T Fukuda, eds. Biological Psychiatry, Vol. 1, Proceedings of the 5th World Congress of Biological Psychiatry, Florence, Italy, 9-14 June, 1991. Amsterdam/London/New York/Tokyo: Excerpta Medica, 1991.
Marder SR, Johnston-Cronk K, Wirshing WC, Eckman T. Schizophrenia and behavioral skills training (chap. 15, pp. 311-28). In: BD Beitman, GL Klerman, eds. Integrating pharmacotherapy and psychotherapy. Washington DC/London: American Psychiatric Press, 1991.
Wirshing WC, Eckman T, Liberman RP, Marder SR. Management of risk of relapse through skills training of chronic schizophrenics (chap. 25, pp. 255-67). In: CA Tamminga, SC Schulz, eds. Schizophrenia research [Vol 1. Advances in neuropsychiatry and psychopharmacology series]. New York: Raven Press, 1991.
Van Putten T, Marder SR, Wirshing WC, Midha KK. Neuroleptic plasma levels in treatment-resistant schizophrenic patients (pp. 67-85). In: B Angrist, SC Schulz, eds. The neuroleptic-nonresponsive patient: Characterization and treatment. (Series Editor: D Spiegel. Progress in psychiatry.) Washington DC/London: American Psychiatric Press, 1990.
Wirshing WC. Psychotherapy with the elderly (pp. 627-32). In: B Guze, senior ed., S Richeimer, DJ Siegal, eds. Handbook of psychiatry. Chicago/London/Boca Raton/Littleton, MA: Yearbook Medical Publishers, 1989.
